JDRF partners with Housey Pharmaceutical Research Laboratories

October 23, 2007

New York, NY and Southfield, MI - October 23, 2007 - The Juvenile Diabetes Research Foundation, the world's largest charitable funder of type 1 diabetes research, today announced a partnership with Housey Pharmaceutical Research Laboratories (HPRL) to support the company's studies to identify compounds to promote the regeneration of functional pancreatic beta cells as a potential treatment for type 1 diabetes.

"We are thrilled to be partnering with Housey Pharmaceutical Research Laboratories on this important program. This drug discovery research is aimed at identifying small molecule compounds to promote beta cell growth and survival based on the company's proprietary technology," said Patricia Kilian, Ph.D., Therapeutic Program Director for Regeneration research at JDRF. "The results from this study may provide a starting point to develop beta cell regeneration therapeutics targeting key scientific pathways, accelerate the pace of drug discovery and development leading to a cure, and have a significant clinical impact on people with diabetes."

"We are very enthusiastic about partnering with JDRF on a project of such fundamental significance in clinical medicine, especially for children," said Gerard Housey, M.D., Ph.D., President of HPRL. We are highly confident with the approach that we are taking and are hopeful that it will lead to substantive advances in the field of diabetes treatment. Furthermore, as a result of the JDRF's creative approach to project support as well as its real-world understanding of modern pharmaceutical industry research, we can now move this project forward more rapidly by partnering with them."

HPRL is the latest company to work with JDRF through its innovative Industry Discovery and Development Partnership program. The IDDP enables JDRF to partner with pharmaceutical, biotech, and medical device businesses that are looking to develop drugs, treatments, technologies, and other therapeutics leading to a cure, reversal, or prevention of type 1 diabetes and its complications.
-end-
Diabetes is a chronic, debilitating disease affecting every organ system. There are two major types of diabetes: type 1 and type 2. Type 1 diabetes is an autoimmune disease in which a person's pancreas stops producing insulin, a hormone that enables people to get energy from food. Type 1 diabetes usually strikes in childhood, adolescence, or young adulthood, but lasts a lifetime. People with type 1 diabetes must take multiple injections of insulin daily or continuous infusion of insulin through a pump just to survive. Type 2 diabetes is a metabolic disorder in which a person's body still produces insulin but is unable to use it effectively. Type 2 is usually diagnosed in adulthood and does not always require insulin injections. Taking insulin does not cure any type of diabetes nor prevent the possibility of its eventual and devastating effects: kidney failure, blindness, nerve damage, amputation, heart attack, and stroke.

About JDRF

JDRF was founded in 1970 by the parents of children with type 1 diabetes -- a disease that strikes children, adolescents, and adults suddenly, makes them insulin dependent for life, and carries the constant threat of devastating complications. Since inception, JDRF has provided more than $1.16 billion to diabetes research worldwide. More than 85 percent of JDRF's expenditures directly support research and research-related education. JDRF's mission is constant: to find a cure for type 1 diabetes and its complications through the support of research. For more information please visit www.jdrf.org

About Housey Pharmaceutical Research Laboratories

HPRL is a private corporation engaged in pharmaceutical discovery research, pharmaceutical technology creation, and technology licensing. The Company's primary efforts are directed toward inventing and developing new drug discovery and creation technologies and utilizing such technologies for the discovery and development of novel therapeutic and preventive medicines. This includes a primary focus on treating unmet medical needs by creating new medicines for human diseases which are either currently untreatable or only partially treatable with existing therapies. For more information visit www.housey.com.

JDRF

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.